Insights into chronic cyclosporine nephrotoxicity

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 11, 1996, Pages 515-519

  Bennett, W M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cyclosporine; Nephrotoxicity; Renin angiotensin; TGF 2 osteopontin

Indexed keywords

ANGIOTENSIN RECEPTOR; CYCLOSPORIN; ENDOTHELIN; NITRIC OXIDE SYNTHASE; OSTEOPONTIN; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA2;

HUMAN; HYPERTENSION; NEPHROTOXICITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY;

ANIMALS; CHRONIC DISEASE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; RATS;

EID: 0029987555     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (39)

1. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian S 1993 Risk factors for chronic rejection in renal allograft recipients. Transplantation 55: 752-757
2. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, William M, Bennett WM 1995 Functional and structural characteristics of experimental FK 506 nephrotoxicity. Clin Exp Pharmacol Physiol 22: 646-654
3. Benigni A, Morigi M, Perico N, Zoja C, Amuchastegui CS, Piccinelli A, Donadelli R, Remuzzi G 1992 The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 54: 775-780
4. Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D, Tillman M, Abrams J, Ryan D, Kelley VK 1995 Delayed omega-3 fatty acid supplements in renal transplantation: A double blind placebo controlled study. Transplantation 59: 352-356
5. Bennett WM, DeMattos A, Meyer MM, Andah T, Barry JM 1996 Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int (in Press)
6. Bennett WM, Lindsley J, Buss WC 1991 The effects of age and dosage route on experimental cyclosporine nephrotoxicity. Transplantation 57: 730-731
7. Bierer BE 1995 Mechanisms of action of immunosuppressive agents: cyclosporin A. FK506, and rapamycin. Proc Assoc Am Physicians 107: 28-40
8. Brezis M, Rosen SN, Epstein FH 1989 The pathophysiological implications of medullary hypoxia. Am J Kidney Dis 13: 253-258
9. Brooks DP, Drutz DJ, Ruffolo RRJ 1990 Prevention and complete reversal of cyclosporine A-induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam. J Pharmacol Exp Ther 254: 375-379
10. Bunke M, Sloan R, Brier M, Ganzel B 1995 An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing. Transplantation 59: 537-540
11. Burdmann EA, Andoh TF, Nast CC, Evan A, Connors BA, Coffman TM, Lindsley J, Bennett WM 1995 Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 269: F491-F499
12. Curtis JJ 1993 Management of hypertension after transplantation. Kidney Int 44: S45-S49
13. Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P 1986 Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 2: 477-479
14. Dunn J, Golden D, Van Buren CT, Lewis RM, Lawen J, Rahan BD 1990 Causes of graft loss beyond two years in the cyclosporine era. Transplantation 49: 349-353
15. Elzinga LW, Rosen S, Bennett WM 1993 Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy : role of sodium intake. J Am Soc Nephrol 4: 214-221
16. Elzinga LW, Rosen S, Burdmann E, Lindsley J, Hatton D, Bennett WM 1994 Effects of renal denervation in a model of chronic cyclosporine nephropathy. J Am Soc Nephrol 5: 920
17. English J, Evan A, Houghton DC, Bennett WM 1987 Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44: 135-141
18. Feutren G, Mihatsch MG 1992 Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326: 1654-1660
19. Fogo A, Hellings SE, Inagami T, Kon V 1992 Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int 42: 770-774
20. Gardner MP, Houghton DC, Andoh TF, Lindsley J, Bennett WM 1996 Clinically relevant doses and blood levels produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition. Transplantation 61: 1506-1512
21. Goodnight SH 1996 The fish oil puzzle. Science and Medicine Sept/Oct: 42-51
22. Hunley TE, Fogo A, Iwasaki S, Kon V 1995 Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 5: 1718-1723
23. Kahan BD 1989 Cyclosporine. N Engl J Med 321: 1725-1738
24. Kahan BD, Dunn J, Fins C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Choc M, Wong R, Hwang DS 1995 Reduced inter-and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 59: 505-511
25. Kahan BD, Grevel J 1988 Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46: 631-644
26. Kelley VE, Kirkman RL, Bastos M, Barrett LV, Strom TB 1989 Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine. Transplantation 48: 98-102
27. Khanna A, Li B, Sehajpal PR, Sharma VR, Suthanthiran M 1995 Mechanism of action of cyclosporine: a new hypothesis implicating transforming growth factor-β. Transplant Rev 9: 41-48
28. McCauley J 1993 The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens 2: 662-669
29. Mihatsch M J, Helmchen U, Casanova P, Habib R, Larsen S, Magil A, Noel LH, Rapola J, Ulrich J, Wallace AC 1991 Kidney biopsy findings in cyclosporine-treated patients with insulin-dependent diabetes mellitus. Klin Wochenschr 69: 354-359
30. Noble S, Markham A 1995 Cyclosporin: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsionbased formulation (Neoral). Drugs 50: 924-941
31. Randhawa PS, Shapiro R, Jordan ML, Stanl TE, Demetris AJ 1993 The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol J 7: 60-68
32. Rogers TS, Ekinga L, Bennett WM, Kelley VE 1988 Selective enhancement of thromboxane in macrophages and kidneys in cyclosporine-induced nephrotoxicity. Dietary protection by fish oil. Transplantation 45: 153-156
33. Rossi NF, Churchill PC, McDonald FD, Ellis VR 1989 Mechanism of cyclosporin A-induced renal vasoconstriction in the rat. J Pharmacol Exp Ther 250: 896-901
34. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM 1994 Vascular mechanisms of cyclosporine-induced hypertension in the rat. J Clin Invest 93: 2244-2250
35. Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, Bruzzi I, Remuzi G 1993 Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 43: 706-711
36. Shihab F, Andoh T, Tanner A, Noble N, Border W, Francheschini N, Bennett WM 1996 Role of transforming growth factor B 1 inexperimental chronic cyclosporine nephropathy. Kidney Int 49: 1141-1151
37. Tresham JJ, Whitworth JA, Scoggins BA, Bennett WM 1990 Cyclosporine-induced hypertension in sheep. The role of thromboxanes. Transplantation 49: 144-148
38. Young BA, Burdmann EA, Johnson RJ, Alpers CE, Giachelli CM, Eng E. Andoh T, Bennett WM, Causer WG, Lindsley J. Duyn J 1995 Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48: 439-448
39. Young B A, Burdmann EA, Johnson RJ, Andoh T, Bennett WM, Couser WG, Alpers CE 1995 Cyclosporine A-induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int 48: 431-438